目的探讨尿常规检测在甲状腺功能亢进症(简称甲亢)临床诊治中的价值。方法选取2021年1月—2023年6月福建省漳州市医院诊治的200例甲亢患者作为研究组,以同期接受健康体检的100名健康自愿者作为对照组。均行尿常规检测和甲状腺激素测定,...目的探讨尿常规检测在甲状腺功能亢进症(简称甲亢)临床诊治中的价值。方法选取2021年1月—2023年6月福建省漳州市医院诊治的200例甲亢患者作为研究组,以同期接受健康体检的100名健康自愿者作为对照组。均行尿常规检测和甲状腺激素测定,对比2组尿pH值、尿蛋白、尿酮体、尿胆红素、尿糖水平及血清游离三碘甲状腺原氨酸(free triiodothyronine,FT3)、游离甲状腺素(free tetraiodothyronine,FT4)及促甲状腺激素(thyroid stimulating hormone,TSH)水平,并分析两者相关性。结果研究组尿pH值为(5.89±1.04),低于对照组的(6.55±0.42),而尿密度值、尿蛋白、尿酮体、尿胆红素、尿糖水平分别为(1.12±0.08)g/cm^(3)、(175.45±22.52)mg/L、(0.74±0.12)mmol/L、(7.12±1.06)mg/L、(2.81±0.45)mmol/L,均高于对照组的(1.01±0.02)g/cm^(3)、(146.25±20.14)mg/L、(0.41±0.20)mmol/L、(4.41±1.05)mg/L、(1.72±0.33)m m o l/L,差异有统计学意义(P<0.05)。研究组血清FT3、FT4分别为(21.22±10.42)p m o l/L、(49.74±18.62)pmol/L,高于对照组的(4.83±0.93)pmol/L、(13.25±1.81)pmol/L,TSH为(0.21±0.03)μIU/mL,低于对照组的(1.62±0.15)μIU/mL,差异有统计学意义(P<0.05)。Pearson相关分析显示,甲亢患者尿常规检查指标尿密度值、尿蛋白、尿酮体、尿胆红素、尿糖与FT3、FT4呈正相关(P<0.05),与TSH呈负相关(P<0.05)。结论甲亢患者尿常规指标相比健康人群有显著变化,与甲状腺激素水平存在相关性,可作为甲亢诊治潜在辅助指标。展开更多
Urine is a potential source of diagnostic biomarkers for detection of diseases,and is a very attractive means of non-invasive biospecimen collection.Nonetheless,proteomic measurement in urine is very challenging becau...Urine is a potential source of diagnostic biomarkers for detection of diseases,and is a very attractive means of non-invasive biospecimen collection.Nonetheless,proteomic measurement in urine is very challenging because diagnostic biomarkers exist in very low concentration(usually below the sensitivity of common immunoassays)and may be subject to rapid degradation.Hydrogel nanoparticles functionalized with Cibacron Blue F3G-A(CB)have been applied to address these challenges for urine biomarker measurement.We chose one of the most difficult low abundance,but medically relevant,hormones in the urine:human growth hormone(hGH).The normal range of hGH in serum is 1 to 10 ng/mL but the urine concentration is suspected to be a thousand times less,well below the detection limit(50 pg/mL)of sensitive clinical hGH immunoassays.We demonstrate that CB particles can capture,preserve and concentrate hGH in urine at physiological salt and urea concentrations,so that hGH can be measured in the linear range of a clinical immunometric assay.Recombinant and cadaveric hGH were captured from synthetic and human urine,concentrated and measured with an Immulite chemiluminescent immunoassay.Values of hGH less than 0.05 ng/mL(the Immulite detection limit)were concentrated to 2 ng/mL,with a urine volume of 1 mL.Dose response studies using 10 mL of urine demonstrated that the concentration of hGH in the particle eluate was linearly dependent on the concentration of hGH in the starting solution,and that all hGH was removed from solution.Thus if the starting urine volume is 100 mL,the detection limit will be 0.1 pg/mL.Urine from a healthy donor whose serum hGH concentration was 1.34 ng/mL was studied in order detect endogenous hGH.Starting from a volume of 33 mL,the particle eluate had an hGH concentration of 58 pg/mL,giving an estimated initial concentration of hGH in urine of 0.175 pg/mL.The nanotechnology described here appears to have the desired precision,accuracy and sensitivity to support large scale clinical studies of urine hGH leve展开更多
文摘目的探讨尿常规检测在甲状腺功能亢进症(简称甲亢)临床诊治中的价值。方法选取2021年1月—2023年6月福建省漳州市医院诊治的200例甲亢患者作为研究组,以同期接受健康体检的100名健康自愿者作为对照组。均行尿常规检测和甲状腺激素测定,对比2组尿pH值、尿蛋白、尿酮体、尿胆红素、尿糖水平及血清游离三碘甲状腺原氨酸(free triiodothyronine,FT3)、游离甲状腺素(free tetraiodothyronine,FT4)及促甲状腺激素(thyroid stimulating hormone,TSH)水平,并分析两者相关性。结果研究组尿pH值为(5.89±1.04),低于对照组的(6.55±0.42),而尿密度值、尿蛋白、尿酮体、尿胆红素、尿糖水平分别为(1.12±0.08)g/cm^(3)、(175.45±22.52)mg/L、(0.74±0.12)mmol/L、(7.12±1.06)mg/L、(2.81±0.45)mmol/L,均高于对照组的(1.01±0.02)g/cm^(3)、(146.25±20.14)mg/L、(0.41±0.20)mmol/L、(4.41±1.05)mg/L、(1.72±0.33)m m o l/L,差异有统计学意义(P<0.05)。研究组血清FT3、FT4分别为(21.22±10.42)p m o l/L、(49.74±18.62)pmol/L,高于对照组的(4.83±0.93)pmol/L、(13.25±1.81)pmol/L,TSH为(0.21±0.03)μIU/mL,低于对照组的(1.62±0.15)μIU/mL,差异有统计学意义(P<0.05)。Pearson相关分析显示,甲亢患者尿常规检查指标尿密度值、尿蛋白、尿酮体、尿胆红素、尿糖与FT3、FT4呈正相关(P<0.05),与TSH呈负相关(P<0.05)。结论甲亢患者尿常规指标相比健康人群有显著变化,与甲状腺激素水平存在相关性,可作为甲亢诊治潜在辅助指标。
基金This work was partly supported by the Italian Istituto Superiore di Sanita’in the framework of the Italy/USA cooperation agreement between the U.S.Department of Health and Human Services,George Mason University and the Italian Ministry of Public HealthThis work was partially supported by the U.S.Department of Energy grant number DE-FC52-04NA25455。
文摘Urine is a potential source of diagnostic biomarkers for detection of diseases,and is a very attractive means of non-invasive biospecimen collection.Nonetheless,proteomic measurement in urine is very challenging because diagnostic biomarkers exist in very low concentration(usually below the sensitivity of common immunoassays)and may be subject to rapid degradation.Hydrogel nanoparticles functionalized with Cibacron Blue F3G-A(CB)have been applied to address these challenges for urine biomarker measurement.We chose one of the most difficult low abundance,but medically relevant,hormones in the urine:human growth hormone(hGH).The normal range of hGH in serum is 1 to 10 ng/mL but the urine concentration is suspected to be a thousand times less,well below the detection limit(50 pg/mL)of sensitive clinical hGH immunoassays.We demonstrate that CB particles can capture,preserve and concentrate hGH in urine at physiological salt and urea concentrations,so that hGH can be measured in the linear range of a clinical immunometric assay.Recombinant and cadaveric hGH were captured from synthetic and human urine,concentrated and measured with an Immulite chemiluminescent immunoassay.Values of hGH less than 0.05 ng/mL(the Immulite detection limit)were concentrated to 2 ng/mL,with a urine volume of 1 mL.Dose response studies using 10 mL of urine demonstrated that the concentration of hGH in the particle eluate was linearly dependent on the concentration of hGH in the starting solution,and that all hGH was removed from solution.Thus if the starting urine volume is 100 mL,the detection limit will be 0.1 pg/mL.Urine from a healthy donor whose serum hGH concentration was 1.34 ng/mL was studied in order detect endogenous hGH.Starting from a volume of 33 mL,the particle eluate had an hGH concentration of 58 pg/mL,giving an estimated initial concentration of hGH in urine of 0.175 pg/mL.The nanotechnology described here appears to have the desired precision,accuracy and sensitivity to support large scale clinical studies of urine hGH leve
